Stanford Study Shows Pulsed Shortwave Therapy Provides Sustained Pain Relief for Thumb Arthritis

A double-blind, randomized controlled clinical trial conducted by researchers at Stanford University has shown that pulsed shortwave therapy provides sustained pain relief in adults with thumb carpometacarpal joint osteoarthritis. The study, which involved 61 adults with clinically and/or radiographically diagnosed thumb CMC osteoarthritis, compared outcomes between participants using an active PSWT device and those using an identical-appearing sham device. Both groups wore their devices for approximately eight hours each night over a four-week period, with significant findings emerging after treatment cessation.

Thumb arthritis represents one of the most common and painful forms of hand arthritis, affecting an estimated 4-7 million U.S. adults with symptomatic thumb CMC arthritis. This condition makes everyday tasks like turning doorknobs, buttoning shirts, or opening jars difficult and painful. Current treatment options remain limited, often involving splints, medications, or injections that may provide temporary relief but fail to address long-term pain management needs. The study abstract detailing these findings can be viewed at https://journals.sagepub.com/doi/10.1177/15589447251371088.

At the four-week mark, both the PSWT and sham groups reported meaningful reductions in pain, likely influenced by the splint-like stiffness of the devices and potential placebo effects. However, the critical distinction emerged after device use was discontinued. By week six, only the PSWT group maintained its pain relief, while the sham group lost their improvement. The difference in pain reduction between PSWT and sham groups at this point was highly statistically significant with a p value of .02, indicating that the benefits were not solely explained by splinting effects, placebo response, or continued device use.

Additional measures including maximum pain, hand function as measured by the Patient-Rated Wrist Hand Evaluation, and single-assessment numeric evaluation scores improved in both groups during the treatment period. The sustained benefit observed in the PSWT group after treatment cessation suggests genuine therapeutic effects beyond temporary mechanical support or psychological factors. PSWT was found to be safe and well tolerated throughout the study period, with adverse events being infrequent and mild, most commonly minor skin irritation from the adhesive tape used with the devices. No serious adverse events were reported in either group.

The implications of these findings are substantial for the millions of adults suffering from thumb arthritis who seek alternatives to medication-based treatments. PSWT represents a non-invasive electromagnetic therapy designed to reduce pain and improve quality of life in patients with chronic musculoskeletal conditions. Unlike medications, PSWT has no systemic side effects and can be self-administered at home, offering convenience and accessibility. BioElectronics Corporation, the developer of this technology, provides more information about their approach at https://www.bielcorp.com/. The study investigators concluded that PSWT may offer true sustained analgesic benefit for thumb osteoarthritis, potentially changing how this widespread condition is managed in clinical practice and at home.